scispace - formally typeset
C

Chern-En Chiang

Researcher at Taipei Veterans General Hospital

Publications -  109
Citations -  7956

Chern-En Chiang is an academic researcher from Taipei Veterans General Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 26, co-authored 76 publications receiving 4788 citations. Previous affiliations of Chern-En Chiang include Mackay Memorial Hospital & National Yang-Ming University.

Papers
More filters
Journal ArticleDOI

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Journal ArticleDOI

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, +798 more
- 27 Oct 2018 - 
TL;DR: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events, and evidence-based glucagon-like peptide 1 receptor agonists should be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events.
Journal ArticleDOI

The long QT syndromes: genetic basis and clinical implications

TL;DR: It is becoming clear that mutations in the KVLQT1, human "ether-a-go-go" related gene, cardiac voltage-dependent sodium channel gene, minK and MiRP1 genes, respectively, are responsible for the LQ tachycardia variants of the Romano-Ward syndrome.
Journal ArticleDOI

Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes

TL;DR: In this exploratory analysis of a randomized trial of patients with HFrEF, dapagliflozin compared with placebo, when added to recommended therapy, significantly reduced the risk of worsening heart failure or cardiovascular death independently of diabetes status.